Apomine

Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) . Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer[1][2].

Product Specifications

CAS Number

[126411-13-0]

Product Name Alternative

SR-45023A; SR 9223i; SK&F-99085

UNSPSC

12352005

Target

Apoptosis; HMG-CoA Reductase (HMGCR)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/apomine.html

Purity

99.67

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CC(P(OC(C)C)(OC(C)C)=O)P(OC(C)C)(OC(C)C)=O)=C1

Molecular Formula

C28H52O7P2

Molecular Weight

562.66

References & Citations

[1]Kuehl PJ, et al. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009;382 (1-2) :104-110.|[2]Edwards CM, et al. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007 Apr 15;120 (8) :1657-63.